Abstract
Purpose
The aim of this systematic review was to identify the interventions used to treat obstructive events, whether thrombotic or non-thrombotic, in long-term central venous catheters (LT-CVC) in cancer patients.
Methods
This review included clinical trials and observational studies reporting the drugs used to treat obstructive catheter events in cancer patients. The authors developed specific search strategies for CINAHL, Cochrane CENTRAL, LILACS, PubMed, Scopus, Web of Science, Google Scholar, Open Grey, and ProQuest. The authors evaluated methodological quality of included studies using criteria from Cochrane’s Collaboration Tool and the Methodological Index for non-randomized studies (MINORS). The quality of evidence was analyzed by using GRADE’s software.
Results
More than 9000 articles were found across the databases. After duplicates removed, the studies were selected in 2 phases. After that, only 15 studies were included. The drugs used to restoration of catheter function were urokinase (53.3%), alteplase (20%), tenecteplase (13.3%), reteplase (6.7%), recombinant urokinase (6.7%), and staphylokinase (6.7%). The results of meta-analysis of 14 studies showed an overall restoration rate of ~ 84%. The drug type meta-analysis demonstrates a success rate of ~ 84%, ~ 92%, and ~ 84% for urokinase, alteplase, and tenecteplase groups, respectively. The main methodological problem in included articles concerns the sample. The quality of evidence ranged from very low to high.
Conclusion
The most common interventions used to treat thrombotic catheter occlusion in cancer patients were urokinase and alteplase. No evidence was found about the treatment for non-thrombotic occlusion, thus elucidating an important gap to be investigated.
Similar content being viewed by others
References
Williams A (2018) Catheter occlusion in home infusion. J Infus Nurs 41(1):52–57. https://doi.org/10.1097/NAN.0000000000000259
Chang DH, Mammadov K, Hickethier T, Borggrefe J, Hellmich M, Maintz D, Kabbasch C (2017) Fibrin sheaths in central venous port catheters: treatment with low-dose, single injection of urokinase on an outpatient basis. Ther Clin Risk Manag 13:111–115. https://doi.org/10.2147/TCRM.S125130
Baskin JL, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, Pui CH, Howard SC (2012) Thrombolytic therapy for central venous catheter occlusion. Haematologica 97(5):641–650. https://doi.org/10.3324/haematol.2011.050492
Massmann A, Jagoda P, Kranzhoefer N, Buecker A (2015) Local low-dose thrombolysis for safe and effective treatment of venous port-catheter thrombosis. Ann Surg Oncol 22(5):1593–1597. https://doi.org/10.1245/s10434-014-4129-0
Toril Rubio M, Rodríguez BMA (2017) Revisión sistemática de las complicaciones de los dispositivos de administración de tratamiento al paciente oncológico. Enferm Glob 16(46):544–561. https://doi.org/10.6018/eglobal.16.2.251571
Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, Howard SC (2009) Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 374:159–169. https://doi.org/10.1016/S0140-6736(09)60220-8
Tolar B, Gould JR (1996) The timing and sequence of multiple device-related complications in patients with long-term indwelling catheters. Cancer 78:1308–1313. https://doi.org/10.1002/(SICI)1097-0142(19960915)78:6<1308::AID-CNCR20>3.0.CO;2-3
Moll S, Kenyon P, Bertoli L, de Maio J, Homesley H, Deitcher SR (2006) Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol 24(19):3056–3060. https://doi.org/10.1200/JCO.2006.05.8438
Verhamme P, Goossens G, Maleux G, Collen D, Stas M (2007) A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion. J Thromb Thrombolysis 24(1):1–5. https://doi.org/10.1007/s11239-006-0006-4
van Miert C, Hill R, Jones L (2012) Interventions for restoring patency of occluded central venous catheter lumens. Cochrane Database of Syst Rev 4:CD007119. https://doi.org/10.1002/14651858.CD007119.pub2
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
Costa ACC, Ribeiro JM, Vasques CI et al (2017) Interventions for treatment of thrombotic occlusion in long-term central venous catheters: a systematic review. PROSPERO CRD42017074256. http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD4201074256
Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 73:712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x
Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration, 2011. URL http://handbook.cochrane.org
Schünemann H, Brożek J, Guyatt G (2013) GRADE handbook for grading quality of evidence and strength of recommendations: the GRADE Working Group. URL guidelinedevelopment.org/handbook
Bjeletich J (1987) Declotting central venous catheters with urokinase in the home by nurse clinicians. NITA 10(6):428–430
Gabrail N, Sandler E, Charu V, Anas N, Lim E, Blaney M, Ashby M, Gillespie BS, Begelman SM (2010) TROPICS1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters. JVIR 21(12):1852–1858 https://doi.org/10.1016/j.jvir.2010.09.002
Haire WD, Lieberman RP, Lund GB, Edney J, Wieczorek BM (1990) Obstructed central venous catheters: restoring function with a 12-hour infusion of a low-dose urokinase. Cancer 66(11):2279–2285. https://doi.org/10.1002/1097-0142(19901201)66:11<2279::AID-CNCR2820661105>3.0.CO;2-O
Haire WD, Lieberman RP (1992) Thrombosed central venous catheters: restoring function with 6-hour urokinase infusion after failure of bolus urokinase. JPEN 16(2):129–132. https://doi.org/10.1177/0148607192016002129
Haire WD, Atkinson JB, Stephens LC, Kotulak GD (1994) Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 72(4):543–547
Haire WD, Deitcher SR, Mullane KM, Jaff MR, Firszt CM, Schulz GA, Schuerr DM, Schwartz LB, Mouginis TL, Barton RP (2004) Recombinant urokinase for restoration of patency in occluded central venous access devices: a double-blind, placebo-controlled trial. Thromb Haemost 92(3):575–582. https://doi.org/10.1160/TH03-11-0686
Horne MK III, Mayo DJ (1997) Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients. J Clin Oncol 15(7):2709–2714. https://doi.org/10.1200/JCO.1997.15.7.2709
Liu CY, Jain V, Shields AF, Heilbrun LK (2004) Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. JVIR 15:39–44. https://doi.org/10.1097/01.RVI.0000106385.63463.EC
Tebbi C, Costanzi J, Shulman R, Dreisbach L, Jacobs BR, Blaney M, Ashby M, Gillespie BS, Begelman SM (2011) A phase III, open-label, single-arm study of tenecteplase for restoration of function in dysfunctional central venous catheters. JVIR 22(8):1117–1123. https://doi.org/10.1016/j.jvir.2011.02.034
Whigham CJ, Greenbaum MC, Fisher RG, Goodman CJ, Thornby JI, Thomas JW (1999) Incidence and management of catheter occlusion in implantable arm ports: results in 391 patients. JVIR 10:767–774. https://doi.org/10.1016/S1051-0443(99)70112-0
Whigham CJ, Lindsey JI, Goodman CJ, Fisher RG (2002) Venous port salvage utilizing low dose tPA. Cardiovasc Intervent Radiol 25(6):513–516. https://doi.org/10.1007/s00270-002-2615-4
Son JT, Min SY, Kim JI, Choi PW, Heo TG, Lee MS, Kim CN, Kim HY, Yi SY, Lee HR, Roh YN (2014) Thrombolytic therapy using urokinase for management of central venous catheter thrombosis. Vasc Spec Int 30(4):144–150. https://doi.org/10.5758/vsi.2014.30.4.144
Deitcher SR, Fraschini G, Himmelfarb J, Schuman E, Smith TJ, Schulz GA, Firszt CM, Mouginis TL (2004) Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients. JVIR 15(6):575–579. https://doi.org/10.1097/01.RVI.0000124950.24134.19
Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey E, COOL Investigators (2001) Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial – the cardiovascular thrombolytic to open occluded lines (COOL) efficacy trial. JVIR 12(8):951–955. https://doi.org/10.1016/S1051-0443(07)61575-9
Haire WD (2001) Techniques in dosing for thrombolysis of occluded central venous catheters. Tech Vasc Interv Radiol 4(2):127–130. https://doi.org/10.1016/S1089-2516(01)90008-3
Ernst FR, Chen E, Lipkin C, Tayama D, Amin AN (2014) Comparison of hospital length of stay, costs, and readmissions of alteplase versus catheter replacement among patients with occluded central venous catheter. J Hosp Med 9(8):490–496. https://doi.org/10.1002/jhm.2208
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
We declare that we have had full control of the primary data extracted for this study, and we agree to allow the journal to revise the data, if it will be requested.
Rights and permissions
About this article
Cite this article
da Costa, A.C.C., Ribeiro, J.M., Vasques, C.I. et al. Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis. Support Care Cancer 27, 407–421 (2019). https://doi.org/10.1007/s00520-018-4500-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-018-4500-y